Vascular Biogenics AerCap Bond
VBLTDelisted Stock | USD 0.28 0.01 3.45% |
Vascular Biogenics holds a debt-to-equity ratio of 0.054. . Vascular Biogenics' financial risk is the risk to Vascular Biogenics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Vascular Biogenics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Vascular Biogenics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Vascular Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Vascular Biogenics' stakeholders.
For most companies, including Vascular Biogenics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Vascular Biogenics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Vascular Biogenics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Vascular |
Given the importance of Vascular Biogenics' capital structure, the first step in the capital decision process is for the management of Vascular Biogenics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Vascular Biogenics to issue bonds at a reasonable cost.
Popular Name | Vascular Biogenics AerCap Global Aviation |
Equity ISIN Code | IL0011327454 |
Bond Issue ISIN Code | US00773HAA59 |
Vascular Biogenics Outstanding Bond Obligations
International Game Technology | US460599AD57 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
AerCap Global Aviation | US00773HAA59 | Details |
Understaning Vascular Biogenics Use of Financial Leverage
Vascular Biogenics' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Vascular Biogenics' current equity. If creditors own a majority of Vascular Biogenics' assets, the company is considered highly leveraged. Understanding the composition and structure of Vascular Biogenics' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. Please read more on our technical analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Vascular Stock
If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.